Phenotypes associated with this allele

• Allele Symbol: Bcl2^tm2.1Lbox
• Allele Name: targeted mutation 2.1, Linda M Boxer
• Allele ID: MGI:5288478
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Bcl2^tm2.1Lbox/Bcl2^tm2.1Lbox	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5288502
ht2	Bcl2^tm2.1Lbox/Bcl2^+	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5288501

Genotype
MGI:5288502

hm1

• Allelic Composition: Bcl2^tm2.1Lbox/Bcl2^tm2.1Lbox
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:175730 )

• with earlier onset of disease than in heterozygous mice

immune system

enlarged spleen ( J:175730 )

• at 4 months

increased B cell number ( J:175730 )

• in the bone marrow and spleen

increased immature B cell number ( J:175730 )

• in the bone marrow and spleen

increased mature B cell number ( J:175730 )

• in the bone marrow and spleen

increased pre-B cell number ( J:175730 )

abnormal B cell physiology ( J:175730 )

• progression through the cell cycle (G0 to G1 and S to G2/M) in B cells is delayed compared to in wild-type cells

• B cells exhibit increased viability compared with wild-type cells

enlarged lymph nodes ( J:175730 )

neoplasm

increased B cell derived lymphoma incidence ( J:175730 )

• with earlier onset of disease than in heterozygous mice

increased follicular lymphoma incidence ( J:175730 )

hematopoietic system

enlarged spleen ( J:175730 )

• at 4 months

increased B cell number ( J:175730 )

• in the bone marrow and spleen

increased immature B cell number ( J:175730 )

• in the bone marrow and spleen

increased mature B cell number ( J:175730 )

• in the bone marrow and spleen

increased pre-B cell number ( J:175730 )

abnormal B cell physiology ( J:175730 )

• progression through the cell cycle (G0 to G1 and S to G2/M) in B cells is delayed compared to in wild-type cells

• B cells exhibit increased viability compared with wild-type cells

growth/size/body

enlarged spleen ( J:175730 )

• at 4 months

Genotype
MGI:5288501

ht2

• Allelic Composition: Bcl2^tm2.1Lbox/Bcl2⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:175730 )

• average age of death is 55 weeks

immune system

enlarged spleen ( J:175730 )

• at 4 months

• 6 to 10 times at 10 to 12 months

increased B cell number ( J:175730 )

• in the bone marrow and spleen

increased immature B cell number ( J:175730 )

• in the bone marrow and spleen

increased mature B cell number ( J:175730 )

• in the bone marrow and spleen

increased pre-B cell number ( J:175730 )

abnormal B cell physiology ( J:175730 )

• progression through the cell cycle (G0 to G1 and S to G2/M) in B cells is delayed compared to in wild-type cells

• B cells exhibit increased viability compared with wild-type cells

enlarged lymph nodes ( J:175730 )

• 5 to 10 times at 10 to 12 months

neoplasm

increased B cell derived lymphoma incidence ( J:175730 )

increased follicular lymphoma incidence ( J:175730 )

• at 7 to 14 months

hematopoietic system

enlarged spleen ( J:175730 )

• at 4 months

• 6 to 10 times at 10 to 12 months

increased B cell number ( J:175730 )

• in the bone marrow and spleen

increased immature B cell number ( J:175730 )

• in the bone marrow and spleen

increased mature B cell number ( J:175730 )

• in the bone marrow and spleen

increased pre-B cell number ( J:175730 )

abnormal B cell physiology ( J:175730 )

• progression through the cell cycle (G0 to G1 and S to G2/M) in B cells is delayed compared to in wild-type cells

• B cells exhibit increased viability compared with wild-type cells

growth/size/body

enlarged spleen ( J:175730 )

• at 4 months

• 6 to 10 times at 10 to 12 months